Revolution Medicines Competitors and Similar CompaniesClear all
Revolution Medicines's competitors and similar companies include Biocon, Shanghai Junshi Biosciences, Takeda Oncology and Kyowa Kirin.
 Revolution Medicines Revolution Medicines (RevMed) is a clinical-stage oncology company that develops therapies for cancer patients. |  Shanghai Junshi Biosciences Shanghai Junshi Biosciences (上海君實生物醫藥科技) is a biopharmaceutical company focused on the treatment of cancer, autoimmune, and metabolic diseases. |  Takeda Oncology Takeda Oncology is a biopharmaceutical company developing medicines for the treatment of oncology and inflammation diseases. |  Kyowa Kirin Kyowa Kirin (formerly Kyowa Hakko Kirin) is a pharmaceutical company focused on the areas of oncology, nephrology, immunology, and the central nervous system. | ||
Founding Date | Founding Date 2014 | Founding Date 1978 | Founding Date 2012 | Founding Date 1993 | Founding Date 2008 |
Type | Type Public | Type Public | Type Public | Type Subsidiary | Type Public |
Tags | |||||
Locations | Locations Redwood City, US HQ Redwood City, US | Locations Bengaluru, IN HQ Bengaluru, IN Nanakramguda, IN Dublin, IE Kuala Lumpur, MY Puchong, MY Delémont, CH see more | Locations Shanghai, CN HQ | Locations Cambridge, US HQ | |
Employees | Employees 37854% increase | Employees 16,5612% increase | Employees 2,578 | Employees 1,6441% decrease | Employees 5,669 |
Valuation ($) | Valuation ($) 8.4 b | Valuation ($) N/A | Valuation ($) N/A | Valuation ($) N/A | Valuation ($) 8.8 b |
Financial | |||||
Revenue (est.) | Revenue (est.) N/A | Revenue (est.) ₹167.8b (FY, 2026) | Revenue (est.) ¥2.4b (FY, 2025) | Revenue (est.) N/A | Revenue (est.) ¥496.8b (FY, 2025) |
Cost of goods | Cost of goods N/A | Cost of goods ₹56.9b (FY, 2026) | Cost of goods ¥466.5m (FY, 2025) | Cost of goods N/A | Cost of goods ¥114.3b (FY, 2025) |
Gross profit | Gross profit N/A | Gross profit ₹115.8b (FY, 2026) | Gross profit ¥2b (FY, 2025) | Gross profit N/A | Gross profit ¥383.4b (FY, 2025) |
Net income | Net income ($1.1b) (FY, 2025) | Net income ₹3.7b (FY, 2026) | Net income (¥1b) (FY, 2025) | Net income N/A | Net income ¥67b (FY, 2025) |
For sources of this data, please see the company profile
View Company Profiles
Biocon
HQ
Bengaluru, IN
Employees
16,561↑ 2% increase
Biocon is a company that develops and manufactures biopharmaceutical products.
View companyShanghai Junshi Biosciences
HQ
Shanghai, CN
Employees
2,578
Shanghai Junshi Biosciences (上海君實生物醫藥科技) is a biopharmaceutical company focused on the treatment of cancer, autoimmune, and metabolic diseases.
View companyTakeda Oncology
HQ
Cambridge, US
Takeda Oncology is a biopharmaceutical company developing medicines for the treatment of oncology and inflammation diseases.
View companyKyowa Kirin
HQ
Tokyo, JP
Employees
5,669
Kyowa Kirin (formerly Kyowa Hakko Kirin) is a pharmaceutical company focused on the areas of oncology, nephrology, immunology, and the central nervous system.
View company